Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-10-05

AUTHORS

Yoshikazu Utsu, Koji Takaishi, Shunichirou Inagaki, Hironori Arai, Hiromi Yuasa, Shinichi Masuda, Yasuhiro Matsuura, Nobuyuki Aotsuka, Hisashi Wakita

ABSTRACT

Dose intensity (DI) of chemotherapy affects prognosis of diffuse large B cell lymphoma (DLBCL). Myelotoxicity is the major dose-limiting toxicity (DLT) of most cytotoxic agents for hematological malignancies, whereas DLT of vincristine (VCR) is mainly neurological toxicity. Although VCR is a key drug and its combination with other cytotoxic agents needs consideration, studies focused on relative DI (RDI) of VCR have not been done before. We retrospectively analyzed 86 cases of DLBCL that received six or more cycles of cyclophosphamide (CPM), doxorubicin (DXR), VCR, prednisolone, and rituximab [R-CHOP] and calculated RDI of each cytotoxic agent to analyze its influence on treatment outcome. The median RDI of CPM, doxorubicin, and VCR was 80.0, 81.7, and 78.4 %, respectively (p = 0.002). The average RDI (ARDI) of these three agents was 80.0 %. The overall survival was significantly worse in the low ARDI (<85 %) than in the high ARDI (>85 %) group (2-year survival rate 67.2 vs 93.4 %, p = 0.011). The survival rate with low RDI VCR (<85 %) was lower than that with high RDI VCR (>85 %), even when the remaining two agents had high ARDI (2-year survival rate 74.3 vs 95.8 %, p = 0.047). In conclusion, VCR dose tended to be reduced compared with CPM and DXR in R-CHOP. Lower ARDI of cytotoxic agents and lower RDI of VCR could lead to poor prognosis in the treatment of DLBCL with R-CHOP. We thought these observations should be confirmed in a prospective study. More... »

PAGES

41-47

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-015-2514-9

DOI

http://dx.doi.org/10.1007/s00277-015-2514-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013177223

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26435364


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Murine-Derived", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, Large B-Cell, Diffuse", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Utsu", 
        "givenName": "Yoshikazu", 
        "id": "sg:person.01007725661.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007725661.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takaishi", 
        "givenName": "Koji", 
        "id": "sg:person.0776770323.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776770323.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inagaki", 
        "givenName": "Shunichirou", 
        "id": "sg:person.01256762775.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256762775.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arai", 
        "givenName": "Hironori", 
        "id": "sg:person.01325076175.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325076175.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuasa", 
        "givenName": "Hiromi", 
        "id": "sg:person.0601472075.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601472075.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masuda", 
        "givenName": "Shinichi", 
        "id": "sg:person.01124154261.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124154261.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsuura", 
        "givenName": "Yasuhiro", 
        "id": "sg:person.01216742571.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216742571.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aotsuka", 
        "givenName": "Nobuyuki", 
        "id": "sg:person.0577376767.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577376767.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wakita", 
        "givenName": "Hisashi", 
        "id": "sg:person.0656507753.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656507753.24"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bmt.2012.244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028358194", 
          "https://doi.org/10.1038/bmt.2012.244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1756-9966-28-116", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027098559", 
          "https://doi.org/10.1186/1756-9966-28-116"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-010-0956-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002676992", 
          "https://doi.org/10.1007/s00277-010-0956-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-015-1287-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021003853", 
          "https://doi.org/10.1186/s12885-015-1287-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-007-0399-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037563009", 
          "https://doi.org/10.1007/s00277-007-0399-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-10-05", 
    "datePublishedReg": "2015-10-05", 
    "description": "Dose intensity (DI) of chemotherapy affects prognosis of diffuse large B cell lymphoma (DLBCL). Myelotoxicity is the major dose-limiting toxicity (DLT) of most cytotoxic agents for hematological malignancies, whereas DLT of vincristine (VCR) is mainly neurological toxicity. Although VCR is a key drug and its combination with other cytotoxic agents needs consideration, studies focused on relative DI (RDI) of VCR have not been done before. We retrospectively analyzed 86 cases of DLBCL that received six or more cycles of cyclophosphamide (CPM), doxorubicin (DXR), VCR, prednisolone, and rituximab [R-CHOP] and calculated RDI of each cytotoxic agent to analyze its influence on treatment outcome. The median RDI of CPM, doxorubicin, and VCR was 80.0, 81.7, and 78.4\u00a0%, respectively (p\u2009=\u20090.002). The average RDI (ARDI) of these three agents was 80.0\u00a0%. The overall survival was significantly worse in the low ARDI (<85\u00a0%) than in the high ARDI (>85\u00a0%) group (2-year survival rate 67.2 vs 93.4\u00a0%, p\u2009=\u20090.011). The survival rate with low RDI VCR (<85\u00a0%) was lower than that with high RDI VCR (>85\u00a0%), even when the remaining two agents had high ARDI (2-year survival rate 74.3 vs 95.8\u00a0%, p\u2009=\u20090.047). In conclusion, VCR dose tended to be reduced compared with CPM and DXR in R-CHOP. Lower ARDI of cytotoxic agents and lower RDI of VCR could lead to poor prognosis in the treatment of DLBCL with R-CHOP. We thought these observations should be confirmed in a prospective study.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-015-2514-9", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "95"
      }
    ], 
    "keywords": [
      "diffuse large B-cell lymphoma", 
      "dose-limiting toxicity", 
      "large B-cell lymphoma", 
      "average RDI", 
      "B-cell lymphoma", 
      "R-CHOP", 
      "dose intensity", 
      "cytotoxic agents", 
      "relative di", 
      "cell lymphoma", 
      "major dose-limiting toxicity", 
      "treatment of DLBCL", 
      "relative dose intensity", 
      "most cytotoxic agents", 
      "cases of DLBCL", 
      "VCR dose", 
      "overall survival", 
      "neurological toxicity", 
      "prospective study", 
      "poor prognosis", 
      "key drug", 
      "treatment outcomes", 
      "hematological malignancies", 
      "dose reduction", 
      "cyclophosphamide", 
      "vincristine", 
      "survival rate", 
      "doxorubicin", 
      "prognosis", 
      "lymphoma", 
      "more cycles", 
      "outcomes", 
      "agents", 
      "toxicity", 
      "myelotoxicity", 
      "prednisolone", 
      "chemotherapy", 
      "malignancy", 
      "dose", 
      "drugs", 
      "survival", 
      "treatment", 
      "study", 
      "conclusion", 
      "group", 
      "cases", 
      "rate", 
      "reduction", 
      "combination", 
      "influence", 
      "cycle", 
      "intensity", 
      "observations", 
      "consideration"
    ], 
    "name": "Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma", 
    "pagination": "41-47", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013177223"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-015-2514-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26435364"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-015-2514-9", 
      "https://app.dimensions.ai/details/publication/pub.1013177223"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_679.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-015-2514-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2514-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2514-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2514-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2514-9'


 

This table displays all metadata directly associated to this object as RDF triples.

267 TRIPLES      21 PREDICATES      103 URIs      90 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-015-2514-9 schema:about N1c08d2307f5a4ba29ef35b2fb53e279a
2 N1c8c24baf294434ea3a19a002c2fbc25
3 N2265aaa65e444d498af748dc0620a2eb
4 N53db1c7708824e879f40afa272e24ed9
5 N6ea97e9f2c574e40be75297bd868547b
6 N87b8da9fc5ff480d80cd3f065489ea23
7 N8eae79974efd484d80dfe762843aa0f4
8 N923f1dff5cbf4874a9a1546d16bf661e
9 N9916b76a475144deb3f94f0019557ae2
10 N99c9fea1894f448eac45a51419ac4299
11 N9be6cb64e1a648f9a00479ee22a91472
12 N9f86044541ee4aae9723ea6c2781306c
13 Nc5eebda84ff844eebb661327deea427c
14 Nd5b95f963ca24538b8fd2632f96a57a5
15 Nd9d4a1b3a3fd4264b47c65351263b5ea
16 Ne3fe6e3f40314146abf619e5cbee37cc
17 Ne5b3ffa225a74671aac7bc7f4d0f5230
18 Nedd3ef27d140436fa6fda65ceba00e81
19 Nfa963ffed3f047a39aa5147be26fa1a3
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author N3b8cfb7e682143b883cea8e2c4726475
23 schema:citation sg:pub.10.1007/s00277-007-0399-y
24 sg:pub.10.1007/s00277-010-0956-7
25 sg:pub.10.1038/bmt.2012.244
26 sg:pub.10.1186/1756-9966-28-116
27 sg:pub.10.1186/s12885-015-1287-9
28 schema:datePublished 2015-10-05
29 schema:datePublishedReg 2015-10-05
30 schema:description Dose intensity (DI) of chemotherapy affects prognosis of diffuse large B cell lymphoma (DLBCL). Myelotoxicity is the major dose-limiting toxicity (DLT) of most cytotoxic agents for hematological malignancies, whereas DLT of vincristine (VCR) is mainly neurological toxicity. Although VCR is a key drug and its combination with other cytotoxic agents needs consideration, studies focused on relative DI (RDI) of VCR have not been done before. We retrospectively analyzed 86 cases of DLBCL that received six or more cycles of cyclophosphamide (CPM), doxorubicin (DXR), VCR, prednisolone, and rituximab [R-CHOP] and calculated RDI of each cytotoxic agent to analyze its influence on treatment outcome. The median RDI of CPM, doxorubicin, and VCR was 80.0, 81.7, and 78.4 %, respectively (p = 0.002). The average RDI (ARDI) of these three agents was 80.0 %. The overall survival was significantly worse in the low ARDI (<85 %) than in the high ARDI (>85 %) group (2-year survival rate 67.2 vs 93.4 %, p = 0.011). The survival rate with low RDI VCR (<85 %) was lower than that with high RDI VCR (>85 %), even when the remaining two agents had high ARDI (2-year survival rate 74.3 vs 95.8 %, p = 0.047). In conclusion, VCR dose tended to be reduced compared with CPM and DXR in R-CHOP. Lower ARDI of cytotoxic agents and lower RDI of VCR could lead to poor prognosis in the treatment of DLBCL with R-CHOP. We thought these observations should be confirmed in a prospective study.
31 schema:genre article
32 schema:isAccessibleForFree false
33 schema:isPartOf N6d8f4840d3884197a0bf883b1dd3294e
34 N7a313bee4a1a412aa2490588ebed3c2d
35 sg:journal.1358129
36 schema:keywords B-cell lymphoma
37 R-CHOP
38 VCR dose
39 agents
40 average RDI
41 cases
42 cases of DLBCL
43 cell lymphoma
44 chemotherapy
45 combination
46 conclusion
47 consideration
48 cycle
49 cyclophosphamide
50 cytotoxic agents
51 diffuse large B-cell lymphoma
52 dose
53 dose intensity
54 dose reduction
55 dose-limiting toxicity
56 doxorubicin
57 drugs
58 group
59 hematological malignancies
60 influence
61 intensity
62 key drug
63 large B-cell lymphoma
64 lymphoma
65 major dose-limiting toxicity
66 malignancy
67 more cycles
68 most cytotoxic agents
69 myelotoxicity
70 neurological toxicity
71 observations
72 outcomes
73 overall survival
74 poor prognosis
75 prednisolone
76 prognosis
77 prospective study
78 rate
79 reduction
80 relative di
81 relative dose intensity
82 study
83 survival
84 survival rate
85 toxicity
86 treatment
87 treatment of DLBCL
88 treatment outcomes
89 vincristine
90 schema:name Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma
91 schema:pagination 41-47
92 schema:productId N777ba6a67055466ca2d53fcbbc63a262
93 N791f80a7c46240edb684ab2722184bfb
94 Nfbda23b15c8649378413bfa4d840d188
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013177223
96 https://doi.org/10.1007/s00277-015-2514-9
97 schema:sdDatePublished 2022-08-04T17:04
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher Nd55414f8bafa49da8e887e98f45a5096
100 schema:url https://doi.org/10.1007/s00277-015-2514-9
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N03f6c4aed98e4180bde5ca2ec28f3e17 rdf:first sg:person.0577376767.42
105 rdf:rest Nd64c7d5776684f4a910408385b673e49
106 N1c08d2307f5a4ba29ef35b2fb53e279a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Cyclophosphamide
108 rdf:type schema:DefinedTerm
109 N1c8c24baf294434ea3a19a002c2fbc25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Humans
111 rdf:type schema:DefinedTerm
112 N2265aaa65e444d498af748dc0620a2eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Aged
114 rdf:type schema:DefinedTerm
115 N383f48c33e1046ca91a7f50b7f198c54 rdf:first sg:person.01124154261.81
116 rdf:rest N979218f8e25241d48f77b1699317a74e
117 N3b8cfb7e682143b883cea8e2c4726475 rdf:first sg:person.01007725661.75
118 rdf:rest Nd1b9067cad9c420095eac5ad8d40f26a
119 N53db1c7708824e879f40afa272e24ed9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Vincristine
121 rdf:type schema:DefinedTerm
122 N6d8f4840d3884197a0bf883b1dd3294e schema:volumeNumber 95
123 rdf:type schema:PublicationVolume
124 N6ea97e9f2c574e40be75297bd868547b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Aged, 80 and over
126 rdf:type schema:DefinedTerm
127 N777ba6a67055466ca2d53fcbbc63a262 schema:name doi
128 schema:value 10.1007/s00277-015-2514-9
129 rdf:type schema:PropertyValue
130 N791f80a7c46240edb684ab2722184bfb schema:name dimensions_id
131 schema:value pub.1013177223
132 rdf:type schema:PropertyValue
133 N7a313bee4a1a412aa2490588ebed3c2d schema:issueNumber 1
134 rdf:type schema:PublicationIssue
135 N87b8da9fc5ff480d80cd3f065489ea23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Drug Administration Schedule
137 rdf:type schema:DefinedTerm
138 N8eae79974efd484d80dfe762843aa0f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Female
140 rdf:type schema:DefinedTerm
141 N923f1dff5cbf4874a9a1546d16bf661e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Antineoplastic Combined Chemotherapy Protocols
143 rdf:type schema:DefinedTerm
144 N979218f8e25241d48f77b1699317a74e rdf:first sg:person.01216742571.83
145 rdf:rest N03f6c4aed98e4180bde5ca2ec28f3e17
146 N988763ee2e7c47dea957333408374a02 rdf:first sg:person.01256762775.74
147 rdf:rest Nf49d46e6dcb54e95a7e1e4cab39cd113
148 N9916b76a475144deb3f94f0019557ae2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Lymphoma, Large B-Cell, Diffuse
150 rdf:type schema:DefinedTerm
151 N99c9fea1894f448eac45a51419ac4299 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Treatment Outcome
153 rdf:type schema:DefinedTerm
154 N9be6cb64e1a648f9a00479ee22a91472 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Middle Aged
156 rdf:type schema:DefinedTerm
157 N9f86044541ee4aae9723ea6c2781306c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Adult
159 rdf:type schema:DefinedTerm
160 Nc5eebda84ff844eebb661327deea427c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Retrospective Studies
162 rdf:type schema:DefinedTerm
163 Nd1b9067cad9c420095eac5ad8d40f26a rdf:first sg:person.0776770323.61
164 rdf:rest N988763ee2e7c47dea957333408374a02
165 Nd55414f8bafa49da8e887e98f45a5096 schema:name Springer Nature - SN SciGraph project
166 rdf:type schema:Organization
167 Nd5b95f963ca24538b8fd2632f96a57a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Rituximab
169 rdf:type schema:DefinedTerm
170 Nd64c7d5776684f4a910408385b673e49 rdf:first sg:person.0656507753.24
171 rdf:rest rdf:nil
172 Nd950d6bc1ea843a78fbe0610c753d094 rdf:first sg:person.0601472075.05
173 rdf:rest N383f48c33e1046ca91a7f50b7f198c54
174 Nd9d4a1b3a3fd4264b47c65351263b5ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Doxorubicin
176 rdf:type schema:DefinedTerm
177 Ne3fe6e3f40314146abf619e5cbee37cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Prednisone
179 rdf:type schema:DefinedTerm
180 Ne5b3ffa225a74671aac7bc7f4d0f5230 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Survival Rate
182 rdf:type schema:DefinedTerm
183 Nedd3ef27d140436fa6fda65ceba00e81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Male
185 rdf:type schema:DefinedTerm
186 Nf49d46e6dcb54e95a7e1e4cab39cd113 rdf:first sg:person.01325076175.04
187 rdf:rest Nd950d6bc1ea843a78fbe0610c753d094
188 Nfa963ffed3f047a39aa5147be26fa1a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Antibodies, Monoclonal, Murine-Derived
190 rdf:type schema:DefinedTerm
191 Nfbda23b15c8649378413bfa4d840d188 schema:name pubmed_id
192 schema:value 26435364
193 rdf:type schema:PropertyValue
194 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
195 schema:name Medical and Health Sciences
196 rdf:type schema:DefinedTerm
197 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
198 schema:name Oncology and Carcinogenesis
199 rdf:type schema:DefinedTerm
200 sg:journal.1358129 schema:issn 0939-5555
201 1432-0584
202 schema:name Annals of Hematology
203 schema:publisher Springer Nature
204 rdf:type schema:Periodical
205 sg:person.01007725661.75 schema:affiliation grid-institutes:grid.459661.9
206 schema:familyName Utsu
207 schema:givenName Yoshikazu
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007725661.75
209 rdf:type schema:Person
210 sg:person.01124154261.81 schema:affiliation grid-institutes:grid.459661.9
211 schema:familyName Masuda
212 schema:givenName Shinichi
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124154261.81
214 rdf:type schema:Person
215 sg:person.01216742571.83 schema:affiliation grid-institutes:grid.459661.9
216 schema:familyName Matsuura
217 schema:givenName Yasuhiro
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216742571.83
219 rdf:type schema:Person
220 sg:person.01256762775.74 schema:affiliation grid-institutes:grid.459661.9
221 schema:familyName Inagaki
222 schema:givenName Shunichirou
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256762775.74
224 rdf:type schema:Person
225 sg:person.01325076175.04 schema:affiliation grid-institutes:grid.459661.9
226 schema:familyName Arai
227 schema:givenName Hironori
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325076175.04
229 rdf:type schema:Person
230 sg:person.0577376767.42 schema:affiliation grid-institutes:grid.459661.9
231 schema:familyName Aotsuka
232 schema:givenName Nobuyuki
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577376767.42
234 rdf:type schema:Person
235 sg:person.0601472075.05 schema:affiliation grid-institutes:grid.459661.9
236 schema:familyName Yuasa
237 schema:givenName Hiromi
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601472075.05
239 rdf:type schema:Person
240 sg:person.0656507753.24 schema:affiliation grid-institutes:grid.459661.9
241 schema:familyName Wakita
242 schema:givenName Hisashi
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656507753.24
244 rdf:type schema:Person
245 sg:person.0776770323.61 schema:affiliation grid-institutes:grid.459661.9
246 schema:familyName Takaishi
247 schema:givenName Koji
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776770323.61
249 rdf:type schema:Person
250 sg:pub.10.1007/s00277-007-0399-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1037563009
251 https://doi.org/10.1007/s00277-007-0399-y
252 rdf:type schema:CreativeWork
253 sg:pub.10.1007/s00277-010-0956-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002676992
254 https://doi.org/10.1007/s00277-010-0956-7
255 rdf:type schema:CreativeWork
256 sg:pub.10.1038/bmt.2012.244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028358194
257 https://doi.org/10.1038/bmt.2012.244
258 rdf:type schema:CreativeWork
259 sg:pub.10.1186/1756-9966-28-116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027098559
260 https://doi.org/10.1186/1756-9966-28-116
261 rdf:type schema:CreativeWork
262 sg:pub.10.1186/s12885-015-1287-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021003853
263 https://doi.org/10.1186/s12885-015-1287-9
264 rdf:type schema:CreativeWork
265 grid-institutes:grid.459661.9 schema:alternateName Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan
266 schema:name Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan
267 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...